2026-10-01 Product Bull
Merck's Tulisokibart Meets Primary Endpoint in Phase IIb HS Study High and medium doses showed superiority over placebo at week 16, supporting HS pipeline progress
D1 -1.0% · +5d -1.0%
2026-09-29 → 10-01 Capital
Merck to Hold Q3 2026 Earnings Call on Oct 29 Company confirms Oct 29 Q3 release; consensus EPS $2.25, revenue $17.52B
D1 +0.4% · +5d -4.9%
› 2 waves of this story2026-09-29 $400M upfront expands precision oncology pipeline targeting common cancer mutation2026-10-01 Company confirms Oct 29 Q3 release; consensus EPS $2.25, revenue $17.52B2026-09-28 → 09-29 Capital
Merck's $2.13B Cancer Drug Licensing Deal with SciBrunch Adds $400M upfront and KRAS G12D inhibitor details; stock slips 1.5%
D1 -0.1% · +5d -6.2%
› 2 waves of this story2026-09-28 $400M upfront, boosts oncology pipeline, reflects US drugmakers' China licensing trend2026-09-29 Adds $400M upfront and KRAS G12D inhibitor details; stock slips 1.5%2026-09-25 → 09-28 Regulation Bull
FDA expands Merck's Welireg label for advanced kidney cancer, adding third indication FDA approval adds new indication, sales climb, wider use
D1 +0.5% · +5d -3.0%
› 2 waves of this story2026-09-25 FDA approval for belzutifan plus lenvatinib in previously treated advanced ccRCC, expanding oncology portfolio.2026-09-28 FDA approval adds new indication, sales climb, wider use2026-09-25 Product Bear
Merck Voluntarily Withdraws I-DXd BLA for ES-SCLC Voluntary withdrawal of BLA for ifinatamab deruxtecan in pretreated ES-SCLC, a setback for oncology pipeline.
D1 +0.5% · +5d -3.0%
2026-09-24 Product Bull
Merck's Remigromig Meets Primary Endpoint in Pivotal DME Trial BRUNELLO study met primary endpoint, offering potential new treatment for diabetic macular edema
D1 -0.1% · +5d -2.8%
2026-09-22 Product Bull
Merck's WINREVAIR FDA Label Update Includes HYPERION Data FDA approves label update for WINREVAIR, adding Phase 3 data in newly diagnosed PAH, boosting product position
D1 +0.9% · +5d -1.1%
2026-09-21 Product Bull
Merck's Subcutaneous Keytruda Approved in Japan Japan approves KEYTRUDA QLEX SC for all approved Keytruda indications
D1 +1.8% · +5d -0.5%
2026-09-18 → 09-21 Product Bull
Merck's Keytruda+Padcev Gets CHMP Positive Opinion in EU CHMP backs combo as perioperative treatment for resectable MIBC
D1 -0.2% · +5d +1.3%
› 2 waves of this story2026-09-18 EU panel recommends approval for perioperative treatment of resectable MIBC2026-09-21 CHMP backs combo as perioperative treatment for resectable MIBC2026-09-08 Product Bull
Merck's Keytruda-Moderna Combo Drives Stock Near 52-Week High Zacks cites positive Phase III data; Keytruda peak sales projected at $35B by 2028
D1 -1.2% · +5d -3.1%
2026-09-03 Company Bear
Merck's Keytruda Biosimilar Set to Enter US Market Cipla and Qilu partner to launch Keytruda biosimilar in US, potentially impacting Merck's key product
D1 +0.5% · +5d -5.5%
2026-08-26 Capital
MRK Hits 52-Week High; Institutional Moves Mixed (BlackRock Up, Beverly Hills Down) New high reflects market optimism on melanoma data and pipeline, but institutional actions diverge: Beverly Hills cut 59.7%, BlackRock added 0.5%
D1 -2.1% · +5d -1.0%
2026-08-20 Analyst
2 analyst rating changes (1 up / 1 down) D1 -2.1% · +5d +0.4%
2026-08-19 Other Bull
MRK Hits 52-Week High as Pharma Group Strengthens Multiple sources confirm MRK at 52-week high; pharma among strongest market groups
D1 +12.6% · +5d +0.6%
2026-08-04 → 08-13 Earnings Bull
Merck Q2 beat, raises guidance, analyst upgrades to Buy Analyst upgrades MRK to Buy, PT $143
D1 +0.2% · +5d +1.9%
› 4 waves of this story2026-08-04 Multiple sources confirm Merck's Q2 beat and raised revenue guidance, but cut profit outlook.2026-08-05 Q2 revenue $16.6B beat, Keytruda strong, FY sales guidance raised2026-08-12 Zacks notes Q2 beat and raised guidance, but earnings estimate cuts and patent risks weigh2026-08-13 Analyst upgrades MRK to Buy, PT $1432026-08-12 Analyst
Daiwa Capital upgrades to Outperform D1 +1.9% · +5d +14.5%
2026-08-12 Insider selling
Insider selling $12.3M (2) D1 +1.9% · +5d +14.5%
2026-08-04 8-K filing
8-K: Item 2.02, Item 9.01 D1 +0.2% · +5d +1.9%
2026-08-04 Earnings
Earnings report 第二季度总收入为$16.6 billion，同比增长5%，或按剔除汇率影响增长4%。
D1 +0.2% · +5d +1.9%
2026-08-04 Company Bear
Merck Cuts FY Profit Guidance on Terns Acquisition FY adj EPS guidance cut to $2.66-$2.76 due to Terns acquisition charges
D1 +0.2% · +5d +1.9%
› 2 waves of this story2026-08-04 Merck lowers full-year profit outlook due to charges from Terns acquisition.2026-08-04 FY adj EPS guidance cut to $2.66-$2.76 due to Terns acquisition charges2026-08-03 Earnings
Merck to Report Earnings on Aug 3 Multiple independent sources confirm Merck reports earnings this Tuesday (Aug 3), a key market focus.
D1 -1.9% · +5d +2.5%
2026-07-25 → 08-01 Capital Bull
Bollard Group Lifts Merck Stake by 5.1% in Q1 Arete Wealth raises stake 30.8%, Argent Capital boosts 5236.8%, extending institutional accumulation trend
D1 -0.2% · +5d -2.3%
› 2 waves of this story2026-07-25 Institutional holding change signals long-term capital allocation2026-08-01 Arete Wealth raises stake 30.8%, Argent Capital boosts 5236.8%, extending institutional accumulation trend2026-08-01 Capital Bull
Multiple Institutions Increase Merck Holdings Arete Wealth Advisors raised stake by 30.8%, Argent Capital by 5236.8%, indicating institutional confidence.
D1 -1.9% · +5d +2.5%
2026-07-29 Other Bull
Merck Hits 52-Week High Stock reaches all-time high today, extending recent strength
D1 -1.1% · +5d -1.6%
› 2 waves of this story2026-07-29 Multiple independent sources confirm Merck's stock reached a 52-week high, indicating market strength2026-07-29 Stock reaches all-time high today, extending recent strength2026-07-29 Company Bull
Merck Declares Q4 2026 Dividend of $0.85 per Share Board declares quarterly dividend, continuing shareholder return policy
D1 -1.1% · +5d -1.6%
2026-07-26 Analyst Bull
20 Analysts Rate Merck 'Moderate Buy' with $133.94 Target Coverage count and target price offer consensus benchmark
D1 -0.2% · +5d -2.3%
2026-07-24 Company
Merck Signs Voluntary Licensing Agreements for HIV Drug Alimatravir Covers 129 countries, allows generic makers to produce low-cost versions
D1 +0.5% · +5d -0.7%
2026-07-20 Capital
Dimensional Adds 2.97M MRK Shares; AIA Trims 1.7% Institutional moves signal divergent capital allocation views
D1 -2.4% · +5d +5.1%
